CD30-Positive Neoplastic Cells Present

Clinical trial pipeline · Data from ClinicalTrials.gov

See which CD30-Positive Neoplastic Cells Present trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 2

NCT03007030

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

This phase II trial studies how well brentuximab vedotin works in treating patients with CD30 positive (+) malignant mesothelioma that cannot be removed by surg…

United States55 participantsStarted 2017-04-05

Treatment: Brentuximab Vedotin, Laboratory Biomarker Analysis

All recent trials (3 shown)

WithdrawnPhase 1/2

NCT02729961

Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma

This phase I/II trial studies the side effects and best dose of ceritinib when given together with brentuximab vedotin to see how well they work in treating tre…

United States0Started 2018-01-03

Treatment: Brentuximab Vedotin, Ceritinib

WithdrawnPhase 1

NCT03373305

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

This phase I trial studies the side effects and best dose of lenalidomide when given together with brentuximab vedotin in treating patients with T-cell lymphoma…

United States0Started 2019-03

Treatment: Brentuximab Vedotin, Lenalidomide